$NKTR
Nektar Therapeutics Stock $nktr

$nktr Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000090670922000005 Filed on March 01, 2022

Income Statement

Concept	2021 Q4	2021 Q3	2021
Revenue	$25.01M	$24.92M	$101.9M
YoY Change	6.59%	-17.02%	-33.36%
Cost Of Revenue	$6.163M	$5.311M	$24.90M
YoY Change	42.56%	-4.65%	27.83%
Gross Profit	$18.85M	$19.61M	$77.01M
YoY Change	-1.53%	-19.84%	-42.29%
Gross Profit Margin	75.36%	78.69%	75.57%
Selling, General & Admin	$32.14M	$29.47M	$122.8M
YoY Change	18.61%	9.14%	17.33%
% of Gross Profit	170.55%	150.27%	159.52%
Research & Development	$99.61M	$103.7M	$400.3M
YoY Change	-3.03%	3.19%	-2.06%
% of Gross Profit	528.57%	529.01%	519.76%
Depreciation & Amortization	$3.436M	$3.620M	$13.00M
YoY Change	4.12%	13.13%	4.0%
% of Gross Profit	18.23%	18.46%	16.88%
Operating Expenses	$99.61M	$103.7M	$400.3M
YoY Change	-3.03%	3.19%	-2.06%
Operating Profit	-$112.9M	-$113.6M	-$446.1M
YoY Change	1.98%	10.23%	4.94%
Interest Expense	-$8.329M	$0.00	$0.00
YoY Change	30.14%		-100.0%
% of Operating Profit
Other Income/Expense, Net	-$24.41M	-$16.00M	-$77.18M
YoY Change		190.08%	309.73%
Pretax Income	-$145.6M	-$129.6M	-$523.3M
YoY Change	24.38%	19.37%	17.87%
Income Tax	-$4.000K	$112.0K	$557.0K
% Of Pretax Income
Net Earnings	-$145.6M	-$129.7M	-$523.8M
YoY Change	24.27%	19.45%	17.86%
Net Earnings / Revenue	-582.37%	-520.47%	-514.03%
Basic Earnings Per Share	-$790.00	-$700.00	-$2.86
Diluted Earnings Per Share	-$790.00	-$700.00	-$2.86
COMMON SHARES
Basic Shares Outstanding	184.6M shares	184.1M shares	183.3M shares
Diluted Shares Outstanding		184.1M shares	183.3M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$734.0M	$921.1M	$734.0M
YoY Change	-30.88%	-3.65%	-30.88%
Cash & Equivalents	$25.22M	$54.02M	$25.22M
Short-Term Investments	$708.7M	$867.1M	$708.7M
Other Short-Term Assets	$23.33M	$20.73M	$23.33M
YoY Change	6.41%	-3.8%	6.54%
Inventory	$15.80M	$15.33M	$15.80M
Prepaid Expenses
Receivables	$22.49M	$28.99M	$22.49M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$795.6M	$986.1M	$795.6M
YoY Change	-30.09%	-5.53%	-30.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$60.51M	$58.83M	$177.5M
YoY Change	1.42%	-2.26%	-4.6%
Goodwill	$76.50M	$76.50M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$64.83M	$34.22M	$64.83M
YoY Change	-52.58%	-82.69%	-52.58%
Other Assets	$2.744M	$1.844M	$2.744M
YoY Change	87.82%	29.86%	82.93%
Total Long-Term Assets	$321.6M	$291.1M	$321.6M
YoY Change	-19.75%	-37.37%	-19.76%
TOTAL ASSETS
Total Short-Term Assets	$795.6M	$986.1M	$795.6M
Total Long-Term Assets	$321.6M	$291.1M	$321.6M
Total Assets	$1.117B	$1.277B	$1.117B
YoY Change	-27.4%	-15.34%	-27.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.747M	$23.66M	$9.747M
YoY Change	-55.97%	52.8%	-55.9%
Accrued Expenses	$75.45M	$116.3M	$75.45M
YoY Change	-19.3%	5.26%	-19.3%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$85.20M	$140.0M	$85.20M
YoY Change	-26.41%	10.65%	-26.42%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.592M	$3.869M	$352.5M
YoY Change	-60.0%	17.56%	1.96%
Total Long-Term Liabilities	$3.592M	$3.869M	$352.5M
YoY Change	-60.0%	17.56%	1.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$85.20M	$140.0M	$85.20M
Total Long-Term Liabilities	$3.592M	$3.869M	$352.5M
Total Liabilities	$437.7M	$475.7M	$437.7M
YoY Change	-5.16%	40.87%	-5.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.833B	-$2.687B
YoY Change	22.69%	22.6%
Common Stock	$3.517B	$3.492B
YoY Change	3.77%	3.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$679.5M	$801.5M	$679.5M
YoY Change
Total Liabilities & Shareholders Equity	$1.117B	$1.277B	$1.117B
YoY Change	-27.4%	-15.34%	-27.4%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021
OPERATING ACTIVITIES
Net Income	-$145.6M	-$129.7M	-$523.8M
YoY Change	24.27%	19.45%	17.86%
Depreciation, Depletion And Amortization	$3.436M	$3.620M	$13.00M
YoY Change	4.12%	13.13%	4.0%
Cash From Operating Activities	-$151.5M	-$101.1M	-$412.7M
YoY Change	53.69%	91.91%	31.72%
INVESTING ACTIVITIES
Capital Expenditures	-$5.896M	-$2.936M	$14.99M
YoY Change	227.56%	54.53%	106.52%
Acquisitions
YoY Change
Other Investing Activities	$126.1M	$2.106M	$217.8M
YoY Change	33.43%	-95.84%	-56.75%
Cash From Investing Activities	$120.2M	-$830.0K	$202.8M
YoY Change	29.66%	-101.7%	-59.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.552M	3.663M	$36.24M
YoY Change	-98.29%	128.94%	-145.1%
NET CHANGE
Cash From Operating Activities	-151.5M	-101.1M	-$412.7M
Cash From Investing Activities	120.2M	-830.0K	$202.8M
Cash From Financing Activities	2.552M	3.663M	$36.24M
Net Change In Cash	-28.79M	-98.30M	-$173.7M
YoY Change	-120.13%	3995.96%	-269.35%
FREE CASH FLOW
Cash From Operating Activities	-$151.5M	-$101.1M	-$412.7M
Capital Expenditures	-$5.896M	-$2.936M	$14.99M
Free Cash Flow	-$145.6M	-$98.20M	-$427.6M
YoY Change	50.46%	93.31%	33.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0000906709
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	0-24006
CY2021	dei	Entity Registrant Name EntityRegistrantName	NEKTAR THERAPEUTICS
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3134940
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 Mission Bay Boulevard South
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94158
CY2021	dei	City Area Code CityAreaCode	415
CY2021	dei	Local Phone Number LocalPhoneNumber	482-5300
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2021	dei	Trading Symbol TradingSymbol	NKTR
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	3100000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	186274156	shares
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Redwood City, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25218000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198955000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	708737000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	862941000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22492000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	38889000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	15801000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	15292000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	23333000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	21928000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	795581000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1138005000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	64828000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	136662000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	60510000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59662000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	117025000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	126476000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	76501000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	76501000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2744000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1461000	USD
CY2021Q4	us-gaap	Assets Assets	1117189000	USD
CY2020Q4	us-gaap	Assets Assets	1538767000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9747000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	22139000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15735000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14532000	USD
CY2021Q4	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	26809000	USD
CY2020Q4	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	44207000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	15468000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	20986000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	17441000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	13915000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	85200000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	115779000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	125736000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	136373000	USD
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	27726000	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2021Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	195427000	USD
CY2020Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	200340000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3592000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8980000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	437681000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	461472000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4157000	USD
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	185468000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	185468000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	180091000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	180091000	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	19000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3516641000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3388730000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2295000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2832995000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2309158000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	679508000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1077295000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1117189000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1538767000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	101907000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	152915000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114617000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	24897000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	19477000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21374000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	400269000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	408678000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	434566000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	122844000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	104682000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	98712000	USD
CY2021	nktr	Impairment Of Assets And Other Costs For Terminated Program ImpairmentOfAssetsAndOtherCostsForTerminatedProgram	0	USD
CY2020	nktr	Impairment Of Assets And Other Costs For Terminated Program ImpairmentOfAssetsAndOtherCostsForTerminatedProgram	45189000	USD
CY2019	nktr	Impairment Of Assets And Other Costs For Terminated Program ImpairmentOfAssetsAndOtherCostsForTerminatedProgram	0	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	548010000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	578026000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	554652000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-446103000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-425111000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-440035000	USD
CY2021	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-8023000	USD
CY2020	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2019	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2021	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	47313000	USD
CY2020	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	30267000	USD
CY2019	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	25044000	USD
CY2021	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	-24410000	USD
CY2020	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	0	USD
CY2019	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	0	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2569000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18282000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	46335000	USD
CY2021	us-gaap	Interest Expense InterestExpense	0	USD
CY2020	us-gaap	Interest Expense InterestExpense	6851000	USD
CY2019	us-gaap	Interest Expense InterestExpense	21310000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-77177000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18836000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-523280000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-443947000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-440054000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	557000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	493000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	613000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-523837000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-444440000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-440667000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.86
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.86
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.49
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.49
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.52
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.52
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	183298000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	183298000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	178581000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	178581000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	174993000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	174993000	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-523837000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-444440000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-440667000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1568000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-927000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	5693000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-294000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-363000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-382000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1862000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1290000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	5311000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-525699000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-445730000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-435356000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1717575000	USD
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	23377000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	99795000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-435356000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1405391000	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	23373000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	94261000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-445730000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1077295000	USD
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	33238000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	94674000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-525699000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	679508000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-523837000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-444440000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-440667000	USD
CY2021	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	77746000	USD
CY2020	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	48563000	USD
CY2019	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	36303000	USD
CY2021	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	47313000	USD
CY2020	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	30267000	USD
CY2019	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	25044000	USD
CY2021	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	-24410000	USD
CY2020	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	0	USD
CY2019	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	0	USD
CY2021	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-8023000	USD
CY2020	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2019	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	16703000	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	94674000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	94261000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	99795000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	14146000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	14182000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13156000	USD
CY2021	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	0	USD
CY2020	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	20351000	USD
CY2019	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	0	USD
CY2021	nktr	Amortization Of Premiums Discounts Net And Other Non Cash Transactions AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions	-6730000	USD
CY2020	nktr	Amortization Of Premiums Discounts Net And Other Non Cash Transactions AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions	-3943000	USD
CY2019	nktr	Amortization Of Premiums Discounts Net And Other Non Cash Transactions AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions	11394000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-12397000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1913000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6411000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	509000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2627000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1284000	USD
CY2021	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-2340000	USD
CY2020	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-2743000	USD
CY2019	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-13090000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2688000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-4476000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1190000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-11690000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2382000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	12967000	USD
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1203000	USD
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4697000	USD
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1530000	USD
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-23524000	USD
CY2020	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	8644000	USD
CY2019	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	4349000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198955000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-605000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-5516000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-16565000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-412660000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-313287000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-328681000	USD
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	960689000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	987533000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1380865000	USD
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1166951000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1449304000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1614036000	USD
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	11504000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	41700000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14989000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7258000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26285000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	202777000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	496213000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	206886000	USD
CY2021	nktr	Sale Of Future Royalties Transaction Costs SaleOfFutureRoyaltiesTransactionCosts	3800000	USD
CY2021	nktr	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	0	USD
CY2020	nktr	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	146250000	USD
CY2019	nktr	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	0	USD
CY2021	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	USD
CY2020	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	250000000	USD
CY2019	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	USD
CY2021	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	3000000	USD
CY2020	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	0	USD
CY2019	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	33238000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	23396000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	23355000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	36238000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-80354000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23355000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-92000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-102000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-173737000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	102592000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-98542000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96363000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	194905000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25218000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198955000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96363000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	9742000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	19199000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	325000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	539000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	555000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1057000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2133000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	57691000	USD
CY2021	nktr	Noncash Investing And Financing Activities Accounts Receivable Recognized In Exchange For Long Term Liabilities NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities	0	USD
CY2020	nktr	Noncash Investing And Financing Activities Accounts Receivable Recognized In Exchange For Long Term Liabilities NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities	4000000	USD
CY2019	nktr	Noncash Investing And Financing Activities Accounts Receivable Recognized In Exchange For Long Term Liabilities NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities	0	USD
CY2021Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	798800000	USD
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders’ equity.</span></div>
CY2021	nktr	Net Expense Reimbursements From Collaboration Partner NetExpenseReimbursementsFromCollaborationPartner	21400000	USD
CY2020	nktr	Net Expense Reimbursements From Collaboration Partner NetExpenseReimbursementsFromCollaborationPartner	38700000	USD
CY2021	nktr	Number Of Reporting Units To Evaluate Goodwill For Impairment NumberOfReportingUnitsToEvaluateGoodwillForImpairment	1	reporting_unit
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198955000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25218000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	708737000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	862941000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	64828000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	136662000	USD
CY2021Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	798783000	USD
CY2020Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1198558000	USD
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	11500000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	41700000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1400000	USD
CY2020Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	5100000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	763287000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	12000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	674000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	762625000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1003348000	USD
CY2021Q4	us-gaap	Cash Cash	1250000	USD
CY2020Q4	us-gaap	Cash Cash	6285000	USD
CY2021Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	798783000	USD
CY2020Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1198558000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1100000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	200000	USD
CY2021Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	8100000	USD
CY2020Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	8100000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3166000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2422000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9342000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	10703000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3293000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2167000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	15801000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	15292000	USD
CY2021Q4	nktr	Depreciable Property Plant And Equipment Gross DepreciablePropertyPlantAndEquipmentGross	201386000	USD
CY2020Q4	nktr	Depreciable Property Plant And Equipment Gross DepreciablePropertyPlantAndEquipmentGross	193450000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	148039000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	138488000	USD
CY2021Q4	nktr	Depreciable Property Plant And Equipment Net DepreciablePropertyPlantAndEquipmentNet	53347000	USD
CY2020Q4	nktr	Depreciable Property Plant And Equipment Net DepreciablePropertyPlantAndEquipmentNet	54962000	USD
CY2021Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	7163000	USD
CY2020Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	4700000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	60510000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59662000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13000000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12500000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11000000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	19153000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	18985000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	14697000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	8974000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	8179000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	6408000	USD
CY2021	us-gaap	Lease Cost LeaseCost	28127000	USD
CY2020	us-gaap	Lease Cost LeaseCost	27164000	USD
CY2019	us-gaap	Lease Cost LeaseCost	21105000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	16800000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	16200000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	8400000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	18626000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	20909000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	21572000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	22255000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	22957000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	75411000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	181730000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	37900000	USD
CY2021Q4	nktr	Lessee Operating Lease Liability Tenant Improvement Reimbursements LesseeOperatingLeaseLiabilityTenantImprovementReimbursements	653000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	143177000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	17441000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	125736000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y1M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2020Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	205255000	USD
CY2012Q1	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	0	USD
CY2021	nktr	Royalty Monetization Proceeds RoyaltyMonetizationProceeds	0	USD
	nktr	Royalty Monetization Proceeds RoyaltyMonetizationProceeds	274000000	USD
CY2021	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	77746000	USD
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	333451000	USD
CY2021	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	47313000	USD
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	244273000	USD
CY2021	nktr	Partial Repayment Of Royalty Sale Proceeds PartialRepaymentOfRoyaltySaleProceeds	0	USD
	nktr	Partial Repayment Of Royalty Sale Proceeds PartialRepaymentOfRoyaltySaleProceeds	10000000	USD
CY2021	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sale Of Future Royalties Gross GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross	23522000	USD
	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sale Of Future Royalties Gross GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross	23522000	USD
CY2021Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	198344000	USD
CY2021Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	198344000	USD
CY2021Q4	nktr	Liabilities On Sale Of Future Royalties Unamortized Transaction Costs LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts	2917000	USD
CY2021Q4	nktr	Liabilities On Sale Of Future Royalties Unamortized Transaction Costs LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts	2917000	USD
CY2021Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	195427000	USD
CY2021Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	195427000	USD
CY2021Q4	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	8200000	USD
CY2020	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	55849000	USD
CY2018Q2	nktr	Stock Issued During Period Subject To Lock Up And Stand Still Provisions Period StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod	P5Y
CY2021Q4	nktr	Sale Of Stock Value Authorized In Transaction SaleOfStockValueAuthorizedInTransaction	300000000	USD
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	26107000	shares
CY2021	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	436000	USD
CY2019	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	16975000	USD
CY2021Q4	nktr	Potential Development Milestones PotentialDevelopmentMilestones	1700000000	USD
CY2021	nktr	Change In Control Severance Payment Period For Executives ChangeInControlSeverancePaymentPeriodForExecutives	P12M
CY2021	nktr	Change In Control Severance Payment Period For Executives ChangeInControlSeverancePaymentPeriodForExecutives	P12M
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	94674000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	94261000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	99795000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	187400000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M6D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.012
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.004
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.018
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.638
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.641
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.622
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.07
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.70
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.25
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13637000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	24.30
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2890000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	14.45
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2481000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	12.08
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	504000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	46.25
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13542000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.62
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y7M28D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2711000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8236000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	26.94
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y29D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2267000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	17300000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	15900000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	30600000	USD
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.60
CY2021	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	6000	USD
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3600000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3500000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3500000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-524440000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-445370000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-441494000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1160000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1423000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1440000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-523280000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-443947000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-440054000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	50000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	165000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	139000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	609000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	364000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	495000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	659000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	529000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	634000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-102000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-36000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-21000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-102000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-36000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-21000	USD
CY2021	nktr	Unrecognized Tax Benefits Period Increase Decrease Reasonable Period Of Change UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange	P12M
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	557000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	493000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	613000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-109889000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-93229000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-92411000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4727000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3081000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	10511000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	97914000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	87060000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	104440000	USD
CY2021	nktr	Effective Income Tax Rate Reconciliation Non Deductible Expense For Liability Related Sale Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount	9936000	USD
CY2020	nktr	Effective Income Tax Rate Reconciliation Non Deductible Expense For Liability Related Sale Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount	6356000	USD
CY2019	nktr	Effective Income Tax Rate Reconciliation Non Deductible Expense For Liability Related Sale Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount	5259000	USD
CY2021	nktr	Effective Income Tax Rate Reconciliation Non Cash Royalty Revenue Related To Sales Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount	-7891000	USD
CY2020	nktr	Effective Income Tax Rate Reconciliation Non Cash Royalty Revenue Related To Sales Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount	-7967000	USD
CY2019	nktr	Effective Income Tax Rate Reconciliation Non Cash Royalty Revenue Related To Sales Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount	-7624000	USD
CY2021	us-gaap	Income Tax Reconciliation Disposition Of Assets IncomeTaxReconciliationDispositionOfAssets	4940000	USD
CY2020	us-gaap	Income Tax Reconciliation Disposition Of Assets IncomeTaxReconciliationDispositionOfAssets	0	USD
CY2019	us-gaap	Income Tax Reconciliation Disposition Of Assets IncomeTaxReconciliationDispositionOfAssets	0	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	6627000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	7929000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-672000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	3647000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	3425000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2132000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	557000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	493000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	613000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	564712000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	456284000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	139996000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	132994000	USD
CY2021Q4	nktr	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	34680000	USD
CY2020Q4	nktr	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	35672000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	33408000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	32517000	USD
CY2021Q4	nktr	Deferred Tax Assets Liability Related To The Sale Of Future Royalties DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties	23757000	USD
CY2020Q4	nktr	Deferred Tax Assets Liability Related To The Sale Of Future Royalties DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties	32737000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	6639000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	10651000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	11688000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	813843000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	701892000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	785748000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	670103000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	28095000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	31789000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	27204000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	29707000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	564000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1856000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	27768000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	31563000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	327000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	226000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	115600000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-95000000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	78665000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	77410000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	27419000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2371000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2512000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	49858000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	58000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	193000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	277000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	490000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1450000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	144000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	80604000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	78665000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	77410000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	USD
CY2021	nktr	Number Of Operating Business Segment NumberOfOperatingBusinessSegment	1	segment
CY2021	nktr	Number Of Operating Business Segment NumberOfOperatingBusinessSegment	1	segment
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	101907000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	152915000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114617000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23647000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28330000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24921000	USD
CY2021Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25009000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50573000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48847000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30033000	USD
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23462000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5756000	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7667000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5311000	USD
CY2021Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6163000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3811000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5773000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5570000	USD
CY2020Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4323000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	95604000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	101313000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	103738000	USD
CY2021Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	99614000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	108987000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	96436000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100531000	USD
CY2020Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	102724000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-109392000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-110205000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-113596000	USD
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-112910000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-133631000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-77709000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-103050000	USD
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-110721000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-122967000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-125519000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-129706000	USD
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-145645000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-138651000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-80000000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-108586000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-117203000	USD
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-680
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-680
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-690
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-690
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-700
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-700
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-790
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-790
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.61
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65

Files In Submission

Name	View Source	Status
0000906709-22-000005-index-headers.html	Edgar Link	pending
0000906709-22-000005-index.html	Edgar Link	pending
0000906709-22-000005.txt	Edgar Link	pending
0000906709-22-000005-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nktr-20211231.htm	Edgar Link	pending
nktr-20211231.xsd	Edgar Link	pending
nktr-20211231xexx311.htm	Edgar Link	pending
nktr-20211231xexx312.htm	Edgar Link	pending
nktr-20211231xexx321.htm	Edgar Link	pending
nktr-20211231_cal.xml	Edgar Link	unprocessable
nktr-20211231_def.xml	Edgar Link	unprocessable
nktr-20211231_g1.jpg	Edgar Link	pending
nktr-20211231_htm.xml	Edgar Link	completed
nktr-20211231_lab.xml	Edgar Link	unprocessable
nktr-20211231_pre.xml	Edgar Link	unprocessable
nktr20211231-exx1040.htm	Edgar Link	pending
nktr20211231-exx211.htm	Edgar Link	pending
nktr20211231-exx231.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NKTR
Nektar Therapeutics Stock $nktr

2021 Q4 Form 10-K Financial Statement

#000090670922000005 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR Nektar Therapeutics Stock $nktr

2021 Q4 Form 10-K Financial Statement

#000090670922000005 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR
Nektar Therapeutics Stock $nktr